علاج ورم الغدة الصعترية (ثيموما) غير القابل للجراحة في المرحلة الثالثة أو الرابعة

References

• Treatment options for patients with inoperable stage III and stage IV thymoma include:
• An intergroup trial conducted in the United States reported a predicted 5-year OS rate of 52% in 26 patients who received the PAC chemotherapy regimen (cisplatin, doxorubicin, cyclophosphamide) followed by radiation therapy without surgery.
• The ADOC regimen (doxorubicin, cisplatin, vincristine, cyclophosphamide) was given to 37 patients.
• A study of combined chemotherapy with cisplatin and etoposide reported:
• Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.
• A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.